R01 CA137598/CA/NCI NIH HHS/United States[Grants and Funding] - Search Results

Year	Number of Results
2010	2
2011	2
2012	1
2013	1
2014	4
2015	1
2016	1
2024	0

1

Pharmacologic activation of p53 by small-molecule MDM2 antagonists.

Shen H, Maki CG. Shen H, et al. Curr Pharm Des. 2011;17(6):560-8. doi: 10.2174/138161211795222603. Curr Pharm Des. 2011. PMID: 21391906 Free PMC article. Review.

2

Modeling the Etiology of p53-mutated Cancer Cells.

Perez RE, Shen H, Duan L, Kim RH, Kim T, Park NH, Maki CG. Perez RE, et al. J Biol Chem. 2016 May 6;291(19):10131-47. doi: 10.1074/jbc.M116.724781. Epub 2016 Mar 28. J Biol Chem. 2016. PMID: 27022024 Free PMC article.

3

Two 4N cell-cycle arrests contribute to cisplatin-resistance.

Shen H, Perez RE, Davaadelger B, Maki CG. Shen H, et al. PLoS One. 2013;8(4):e59848. doi: 10.1371/journal.pone.0059848. Epub 2013 Apr 1. PLoS One. 2013. PMID: 23560058 Free PMC article.

4

Increasing cisplatin sensitivity by schedule-dependent inhibition of AKT and Chk1.

Duan L, Perez RE, Hansen M, Gitelis S, Maki CG. Duan L, et al. Cancer Biol Ther. 2014;15(12):1600-12. doi: 10.4161/15384047.2014.961876. Cancer Biol Ther. 2014. PMID: 25482935 Free PMC article.

5

p53-regulated autophagy is controlled by glycolysis and determines cell fate.

Duan L, Perez RE, Davaadelger B, Dedkova EN, Blatter LA, Maki CG. Duan L, et al. Oncotarget. 2015 Sep 15;6(27):23135-56. doi: 10.18632/oncotarget.5218. Oncotarget. 2015. PMID: 26337205 Free PMC article.

6

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

Aziz MH, Shen H, Maki CG. Aziz MH, et al. Oncogene. 2011 Nov 17;30(46):4678-86. doi: 10.1038/onc.2011.185. Epub 2011 Jun 6. Oncogene. 2011. PMID: 21643018 Free PMC article.

7

Novel roles for p53 in the genesis and targeting of tetraploid cancer cells.

Davaadelger B, Shen H, Maki CG. Davaadelger B, et al. PLoS One. 2014 Nov 7;9(11):e110844. doi: 10.1371/journal.pone.0110844. eCollection 2014. PLoS One. 2014. PMID: 25380055 Free PMC article.

8

The prolyl peptidases PRCP/PREP regulate IRS-1 stability critical for rapamycin-induced feedback activation of PI3K and AKT.

Duan L, Ying G, Danzer B, Perez RE, Shariat-Madar Z, Levenson VV, Maki CG. Duan L, et al. J Biol Chem. 2014 Aug 1;289(31):21694-705. doi: 10.1074/jbc.M114.550038. Epub 2014 Jun 16. J Biol Chem. 2014. PMID: 24936056 Free PMC article.

9

p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.

Shen H, Maki CG. Shen H, et al. J Cell Biochem. 2010 Dec 1;111(5):1280-90. doi: 10.1002/jcb.22852. J Cell Biochem. 2010. PMID: 20803550 Free PMC article.

10

Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells.

Moran DM, Maki CG. Moran DM, et al. Mol Cancer Ther. 2010 Apr;9(4):895-905. doi: 10.1158/1535-7163.MCT-09-1220. Epub 2010 Apr 6. Mol Cancer Ther. 2010. PMID: 20371712 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

12 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year